55,015 Shares in Perrigo Company plc (NYSE:PRGO) Acquired by Clear Harbor Asset Management LLC

Clear Harbor Asset Management LLC purchased a new stake in Perrigo Company plc (NYSE:PRGO) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 55,015 shares of the company’s stock, valued at approximately $1,443,000.

Several other hedge funds have also recently bought and sold shares of the stock. Central Pacific Bank Trust Division bought a new stake in shares of Perrigo in the 1st quarter worth about $48,000. TFC Financial Management Inc. boosted its position in Perrigo by 39.7% in the first quarter. TFC Financial Management Inc. now owns 2,462 shares of the company’s stock valued at $79,000 after buying an additional 700 shares in the last quarter. Beach Investment Counsel Inc. PA bought a new stake in Perrigo during the second quarter worth about $72,000. Voisard Asset Management Group Inc. increased its holdings in shares of Perrigo by 520.0% during the second quarter. Voisard Asset Management Group Inc. now owns 4,650 shares of the company’s stock worth $119,000 after buying an additional 3,900 shares in the last quarter. Finally, CWM LLC raised its stake in shares of Perrigo by 877.0% in the second quarter. CWM LLC now owns 8,197 shares of the company’s stock valued at $210,000 after acquiring an additional 7,358 shares during the last quarter. 95.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Katherine C. Doyle sold 8,954 shares of Perrigo stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $27.30, for a total transaction of $244,444.20. Following the completion of the sale, the director now directly owns 6,009 shares of the company’s stock, valued at approximately $164,045.70. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, EVP Ronald Craig Janish sold 13,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $29.40, for a total value of $382,200.00. Following the completion of the transaction, the executive vice president now directly owns 20,553 shares in the company, valued at approximately $604,258.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Katherine C. Doyle sold 8,954 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $27.30, for a total transaction of $244,444.20. Following the transaction, the director now owns 6,009 shares of the company’s stock, valued at approximately $164,045.70. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,254 shares of company stock valued at $1,411,969 over the last ninety days. 0.70% of the stock is currently owned by company insiders.

Perrigo Stock Performance

Shares of PRGO stock opened at $25.09 on Friday. The company’s fifty day simple moving average is $26.66 and its 200-day simple moving average is $27.78. Perrigo Company plc has a 12 month low of $23.89 and a 12 month high of $34.60. The company has a quick ratio of 1.24, a current ratio of 1.99 and a debt-to-equity ratio of 0.80. The firm has a market cap of $3.42 billion, a PE ratio of -358.43 and a beta of 0.48.

Perrigo (NYSE:PRGO) last released its quarterly earnings data on Friday, August 2nd. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.46 by $0.07. The company had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.13 billion. Perrigo had a positive return on equity of 6.79% and a negative net margin of 2.81%. The firm’s revenue for the quarter was down 10.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.63 EPS. Equities research analysts expect that Perrigo Company plc will post 2.56 EPS for the current fiscal year.

Perrigo Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 17th. Investors of record on Friday, August 30th were paid a $0.276 dividend. This represents a $1.10 dividend on an annualized basis and a yield of 4.40%. The ex-dividend date of this dividend was Friday, August 30th. Perrigo’s dividend payout ratio (DPR) is presently -1,571.43%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $42.00 price target on shares of Perrigo in a report on Monday, September 30th. StockNews.com lowered Perrigo from a “buy” rating to a “hold” rating in a research note on Friday. Jefferies Financial Group reissued a “hold” rating and issued a $30.00 price target (down previously from $50.00) on shares of Perrigo in a research note on Monday, September 23rd. Finally, Piper Sandler decreased their price target on shares of Perrigo from $36.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $37.00.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.